Get alerts when ALT reports next quarter
Set up alerts — freeAltimmune fell 16.6% after earnings, despite management’s positive framing. The transcript offers no new financial or clinical setback; the likely source of disappointment is the long wait for the pivotal PERFORMA readout, expected in 2029, with enrollment still ramping and ex-U.S. sites yet to activate.
See ALT alongside your other holdings
Add to your portfolio — freeTrack Altimmune, Inc. in your portfolio with real-time analytics, dividend tracking, and more.
View ALT Analysis